Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 Universal CAR-T in R/R B-cell Malignancies
NCT05105867Phase 1Unknown
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GEN-011 in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Status: unknown.
02
Drugs
GEN-011
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05105867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105867.